Abstract
Distress vocalizations (DV) induced by social isolation were measured in 1-day-old domestic chicks after intracerebroventricular injections of drugs believed to exert their effects through the noradrenergic system. The alpha-adrenoreceptor agonist clonidine reliably suppressed DV rates at doses low as 0.08 micrograms. When given alone, phentolamine, phenoxybenzamine, propranolol, sotalol, and yohimbine (adrenoreceptor antagonists) did not reliably alter DV rates at doses that were not toxic. The clonidine DV suppression was reliably reversed by yohimbine (1.75 micrograms), but by none of the other adrenoceptor antagonists or naloxone. 6-Hydroxydopamine at doses as high as 120 micrograms, which essentially eliminated forebrain norepinephrine, failed to suppress DV rates reliably when given alone and, when given in combination with clonidine (0.1 micrograms) or morphine (0.05 micrograms), failed to reverse the severe DV suppression imposed by these drugs. The results suggest that clonidine suppresses DV rates in or by some means other than prejunctional alpha 2-adrenoreceptor stimulation.
References
Aug 13, 1976·Brain Research·J M Cedarbaum, G K Aghajanian
Dec 1, 1976·European Journal of Pharmacology·W Kobinger, L Pichler
Feb 25, 1977·Brain Research·S J Bird, M J Kuhar
Nov 9, 1978·Nature·G K Aghajanian
Nov 1, 1978·Brain Research Bulletin·J PankseppA J Kastin
Aug 15, 1977·European Journal of Pharmacology·J M Cedarbaum, G K Aghajanian
Jan 1, 1979·The American Journal of Psychiatry·M S GoldH D Kleber
Jul 1, 1979·The American Journal of Psychiatry·M S GoldD E Redmond
Aug 1, 1978·Pharmacology, Biochemistry, and Behavior·B H Herman, J Panksepp
Sep 1, 1978·Pharmacology, Biochemistry, and Behavior·S B Sparber, D R Meyer
May 1, 1978·Pharmacology, Biochemistry, and Behavior·D M Jacobowitz, J S Richardson
Jan 1, 1975·European Journal of Pharmacology·L F TsengE T Wei
Jul 11, 1975·Brain Research·T H SvenssonG K Aghajanian
Jan 1, 1971·Acta Physiologica Scandinavica. Supplementum·L O Farnebo, B Hamberger
Nov 1, 1973·Neuropharmacology·K Starke, H Montel
Sep 1, 1971·British Journal of Pharmacology·L O Farnebo, B Hamberger
Mar 1, 1968·International Journal of Neuropharmacology·L ChiosaA Banaru
Jan 1, 1980·Neuroscience and Biobehavioral Reviews·J PankseppF G DeEskinazi
Jan 27, 1980·Brain Research·R Laverty, R H Roth
Mar 1, 1980·Pharmacology, Biochemistry, and Behavior·J PankseppN J Bean
Citations
Jun 1, 1987·Journal of Autism and Developmental Disorders·T L Sahley, J Panksepp
Jan 1, 1994·Psychopharmacology·S M SiviyD M Atrens
Aug 20, 1984·Brain Research·J T McCabeS F Leibowitz
May 5, 1987·Brain Research·J C Harris, J D Newman
Jan 4, 1991·Brain Research·J D NewmanD L Murphy
May 1, 1985·Pharmacology, Biochemistry, and Behavior·L Normansell, J Panksepp
Oct 1, 1989·Pharmacology, Biochemistry, and Behavior·J W Smythe, B A Pappas
Aug 1, 1988·Brain Research·N H Kalin, S E Shelton
Nov 8, 2001·European Journal of Pharmacology·R ZhangM Furuse
Oct 6, 2006·Behavioural Pharmacology·Jason E WarnickKenneth J Sufka
Mar 21, 2009·Behavioural Pharmacology·Kenneth J SufkaJohn M Rimoldi
Jan 1, 1990·The European Journal of Neuroscience·Gregory F. Ball, Jacques Balthazart
Jan 15, 1997·Annals of the New York Academy of Sciences·J PankseppM Bekkedal
May 16, 2003·Psychological Review·Jaak Panksepp
Nov 5, 2003·Journal of Neuroscience Research·Rong ZhangMitsuhiro Furuse
Apr 20, 2002·Addiction·Jaak PankseppJeff Burgdorf
Aug 7, 2021·Behavioural Brain Research·Yasuko TobariSimone L Meddle
Nov 11, 2021·Frontiers in Neuroendocrinology·Yasuko TobariSimone L Meddle